IDC MarketScape Names Medidata a Leader in Life Science R&D Risk-Based Monitoring Solutions Vendor Assessment
6.2.2023 21:15:00 EET | Business Wire | Press release
Medidata, a Dassault Systèmes company, announced it has been positioned as a Leader in the IDC MarketScape “Worldwide Life Science R&D Risk-Based Monitoring Solutions 2022 Vendor Assessment (doc #US48061722).” The IDC MarketScape assessment evaluated Medidata’s comprehensive RBQM (Risk-Based Quality Management) capabilities including Medidata Detect, which provides clinical operations teams with the ability to proactively monitor and mitigate risks to data integrity and patient safety.
“Our position in the IDC MarketScape comes from the success our customers gain with Medidata’s industry-leading analytics, Detect, and our Professional Services offering,” said Fareed Melhem, senior vice president, Medidata AI. “Clinical trials are faster and have vastly more data than ever before, requiring a seismic shift in how clinical operations and data management teams can–and should–monitor and analyze those data to derive actionable insights.”
Medidata Detect is the end-to-end data and risk surveillance platform, providing cross-functional operational teams with the ability to identify, document, monitor, and mitigate risks to data integrity, and patient safety. Detect users have access to role-based activities and workflows supported by real-time data, visualizations, and automated insights for better planning and increased efficiency.
As with all of its solutions, RBQM customers are supported by the Medidata Professional Services team – recognized experts with deep clinical trial expertise. The team supports rapid implementation and client enablement, process improvements, change management, business transformation, and plays a critical role in ROI maximization.
About the IDC MarketScape
The IDC MarketScape vendor assessment model is designed to provide an overview of the competitive fitness of ICT (information and communications technology) suppliers in a given market. The research methodology utilizes a rigorous scoring methodology based on both qualitative and quantitative criteria that results in a single graphical illustration of each vendor’s position within a given market. IDC MarketScape provides a clear framework in which the product and service offerings, capabilities and strategies, and current and future market success factors of IT and telecommunications vendors can be meaningfully compared. The framework also provides technology buyers with a 360-degree assessment of the strengths and weaknesses of current and prospective vendors.
Medidata is a wholly owned subsidiary of Dassault Systèmes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.
About Medidata
Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes. More than one million registered users across 2,000+ customers and partners access the world's most trusted platform for clinical development, commercial, and real-world data. Medidata, a Dassault Systèmes company (Euronext Paris: FR0014003TT8, DSY.PA), is headquartered in New York City and has offices around the world to meet the needs of its customers. Discover more at www.medidata.com and follow us @Medidata
About Dassault Systèmes
Dassault Systèmes, the 3DEXPERIENCE Company, is a catalyst for human progress. We provide business and people with collaborative 3D virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers push the boundaries of innovation, learning and production to achieve a more sustainable world for patients, citizens, and consumers. Dassault Systèmes brings value to more than 300,000 customers of all sizes, in all industries, in more than 140 countries. For more information, visit www.3ds.com
3DEXPERIENCE, the Compass icon, the 3DS logo, CATIA, BIOVIA, GEOVIA, SOLIDWORKS, 3DVIA, ENOVIA, NETVIBES, MEDIDATA, CENTRIC PLM, 3DEXCITE, SIMULIA, DELMIA, and IFWE are commercial trademarks or registered trademarks of Dassault Systèmes, a French “société européenne” (Versailles Commercial Register # B 322 306 440), or its subsidiaries in the United States and/or other countries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230206005505/en/
Contact information
Tom Paolella
Senior Director, Corporate Communications & Affairs
+1-848-203-7596
thomas.paolella@3ds.com
Paul Oestreicher
External Communications Director
+1-917-522-4692
paul.oestreicher@3ds.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Eaton vahvistaa eurooppalaista tuotantoaan laajentamalla tuotantolaitostaan Itävallassa1.10.2026 10:00:00 EEST | Tiedote
Eaton juhlistaa Itävallassa sijaitsevan Schremsin tuotantolaitoksensa laajennusta 1. lokakuuta 2026. Laajennus vastaa sähköistymisen ja digitalisaation kasvattamaan kysyntään kaikkialla Euroopassa sekä lisää sähköisten suojaus- ja sähkönhallintaratkaisujen alueellista tuotantokapasiteettia. Alle kymmenessä kuukaudessa valmistunut laajennus yhdistää täysin automatisoidun tuotannon, edistyneen digitaalisen integraation ja tuotteiden end-to-end -jäljitettävyyden. Tämä lehdistötiedote sisältää multimediaa. Katso koko julkaisu täällä: https://www.businesswire.com/news/home/20261001549090/fi/ Eaton expanded manufacturing capacity in Europe for power management solutions in Schrems, Austria. ”Asiakkaat investoivat kaikkialla Euroopassa kriittiseen infrastruktuuriin, joka pitää yritykset toiminnassa, tukee talouskasvua ja vastaa kasvavaan sähkön kysyntään. Tämä laajennus kuvastaa jatkuvia investointejamme tuotantoon, teknologiaan ja osaavaan työvoimaan. Samalla se lisää niiden tuotteiden ja ra
Aegir Insights Launches Next-Generation Energy Intelligence Platform1.10.2026 10:00:00 EEST | Press release
Aegir Insights today announced the launch of its next-generation energy intelligence platform, combining commercial data, expert research and investment modeling in a single environment for investment decisions across onshore wind, offshore wind, solar, energy storage and data centers. The Aegir Platform links the intelligence that informs commercial decisions in renewables: Markets, companies, projects, auctions, supply chains and transactions. Together with analyst research and investment software, it gives the full context to assess where to invest, which assets and counterparties to consider, and what determines their viability. "Energy investment depends on understanding how projects, companies and markets fit together," said Scott Urquhart, CEO of Aegir Insights. "An asset's ownership, auction position, supply chain and route to market all shape its investment case. We connect that commercial context to Aegir's established investment modeling, laying the foundation for renewables
Advanced MRI Imaging Reveals Changes in Muscle Composition and Fat Infiltration During Obesity Treatment1.10.2026 09:55:00 EEST | Press release
As obesity treatment continues to evolve, understanding what happens to muscle during weight loss is becoming increasingly important. At the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD),AMRA Medical Chief Scientific Officer Dr. Jennifer Linge will present how advanced MRI-based analysis can provide a more detailed view of changes in muscle composition during obesity treatment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260930545312/en/ Advanced MRI-based analysis can provide a more detailed view of changes in muscle composition during obesity treatment The presentation addresses an increasingly important question in obesity research: what happens to muscle as people lose weight?Understanding muscle composition changes is important because muscle health is about more than muscle size alone. Research using AMRA’s MRI-derived biomarkers has shown that muscle fat infiltration and muscle vo
Ares Strengthens Commitment to Plenitude Through €1 Billion Capital Contribution1.10.2026 09:30:00 EEST | Press release
Ares Management Corporation (NYSE: ARES), a leading global investment manager, announced today that Ares Alternative Credit funds (“Ares”) participated in a reorganization of the shareholding and governance structure of Plenitude through which Ares and Eni S.p.A (“Eni”) upsized their capital contribution by approximately €1.5 billion, of which over €1 billion is attributable to Ares, based on a pre-money equity valuation of Plenitude of €10.75 billion. Following completion of the transaction, Ares holds 26.24% of Plenitude’s share capital, with Eni holding 65.03% and Energy Infrastructure Partners (“EIP”) as an 8.73% shareholder. Ares first invested in Plenitude in 2025, acquiring a 20% stake in the business for approximately €2 billion. This transaction is geared towards strengthening Plenitude’s capital structure and introduces an enhanced governance framework that supports the company’s long-term growth ambitions. Ares and Eni will jointly control Plenitude, with Ares appointing thr
Orifarm Unveils 2031 Strategy to Accelerate Growth Across Europe, With Significant Expansion in Generics1.10.2026 09:10:00 EEST | Press release
With its five-year strategy, Fit to Scale, Orifarm sets out an ambitious path to scale across Europe, including a major expansion of its prescription medicines business from a Nordic footprint to a broader European platform. The strategy aims to double EBITDA to €300m and generate more than €3bn in revenue by 2031, marking the next step in Orifarm's journey as a diversified European pharmaceutical company bringing affordable medicines to more customers, patients and healthcare systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260930257993/en/ Orifarm Headquarter, Odense Denmark “As European healthcare systems face rising demand, budget pressures, and supply challenges, Orifarm is uniquely positioned to improve access to affordable medicines and strengthen European supply. Our Fit to Scale strategy is about playing an even bigger role in meeting these needs and taking Orifarm to the next level,” says Mads Fink Eriksen,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom